MentionFox
Home › Executive changes › SAB Biotherapeutics, Inc.
Leadership changes · SABS · SEC Form 8-K, Item 5.02

Leadership changes at SAB Biotherapeutics, Inc. (2026)

Before you join, sell to or invest in SAB Biotherapeutics, Inc.

MentionFox check on SAB Biotherapeutics, Inc.: only 1 source on file so far (checked 14 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/sab-biotherapeutics

Check SAB Biotherapeutics, Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about SAB Biotherapeutics, Inc.?

Who joined and who left SAB Biotherapeutics, Inc. (SABS)? 1 filing reported on 2026-01-07, each cited to the company's own filing.

As of November 14, 2026, SAB Biotherapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on January 7, 2026 (Form 8-K, January 7, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

Caligan Partners LP also filed stake reports on 9 other companies ↓

Sell to companies like SAB Biotherapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes1
Latest filing2026-01-07

SAB Biotherapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-01-07. Every row below is cited to the filing it comes from, and this page adds each new change as SAB Biotherapeutics, Inc. files it.

Also on the record for SAB Biotherapeutics, Inc.

DateRecordFigureOur pageSource
August 14, 2026Stake report, Schedule 13G/A, by BALYASNY ASSET MANAGEMENT L.P.9.45% of the class5%+ stakesSource
August 14, 2026Stake report, Schedule 13G/A, by Caligan Partners LP8.8% of the class5%+ stakesSource
August 14, 2026Stake report, Schedule 13G/A, by Commodore Capital LP9.9% of the class5%+ stakesSource
August 14, 2026Stake report, Schedule 13G/A, by Perceptive Advisors LLC7.3% of the class5%+ stakesSource
August 14, 2026Stake report, Schedule 13G/A, by Vivo Opportunity Fund Holdings, L.P.9.99% of the class5%+ stakesSource
August 14, 2026Stake report, Schedule 13G/A, by Woodline Partners LP6.8% of the class5%+ stakesSource
August 12, 2026Stake report, Schedule 13G, by Adage Capital Management, L.P.8.38% of the class5%+ stakesSource
August 10, 2026Stake report, Schedule 13D/A, by RA Capital Management, L.P.9.9% of the class5%+ stakesSource
May 15, 2026Stake report, Schedule 13G, by Balyasny Asset Management L.P.9.99% of the class5%+ stakesSource
May 15, 2026Stake report, Schedule 13G, by Caligan Partners LP10.4% of the class5%+ stakesSource
May 15, 2026Stake report, Schedule 13G/A, by Perceptive Advisors LLC8.4% of the class5%+ stakesSource
May 1, 2026Stake report, Schedule 13G, by Millennium Management LLC5.1% of the class5%+ stakesSource

Selling to them or working with them? See who runs SAB Biotherapeutics, Inc. now and the warning signs.

Free to see. No signup.

Keep reading

More on SAB Biotherapeutics, Inc. and the records around it.

SAB Biotherapeutics, Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on SAB Biotherapeutics, Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on SAB Biotherapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on SAB Biotherapeutics, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    13 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The newest 12 of 23 records.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-01-07Reportednot named in the filing8-K, 2026-01-07
Selling to SAB Biotherapeutics, Inc.?

New leaders reset buying decisions — get the Full Report on SAB Biotherapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch SAB Biotherapeutics, Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the senior executive at SAB Biotherapeutics, Inc., with the record behind each one.

Find candidates like senior executive at SAB Biotherapeutics, Inc.

Every change, in the filing's words

Filed 2026-01-07 · 8-K

Reported

On January 5, 2026, the Board of Directors (the "Board") of SAB Biotherapeutics, Inc., a Delaware corporation (the "Company"), following the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed, David Zaccardelli, Pharm.D, and Rita Jain, M.D. each to serve as a Class II director of the Company, effective January 5, 2026, and to serve until the Company's 2026 annual meeting of stockholders or until their respective successors are duly elected and qualified.

Also stated in this filing

  • Dr. Zaccardelli will act as Chairperson of the Board.
  • Samuel J. Reich, the Company's Chief Executive Officer and former Chairperson, will continue to serve as a member of the Board.
  • Each of Dr. Jain and Dr. Zaccardelli were appointed to the Board at the recommendation of RA Capital Healthcare Fund, L.P. ("RA Capital") pursuant to the letter agreement entered into between the Company and RA Capital dated July 21, 2025 in connection with the Company's July 2025 private placement of securities.
  • Each of Dr. Zaccardelli or Dr. Jain will receive compensation similar to the other non-employee members of the Board as described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as filed with the Securities and Exchange Commission on March 31, 2025 (the "Annual Report"), as such compensation may be amended from time to time.
  • David Zaccardelli, Pharm.D., served as the President, Chief Executive Officer and member of the board of directors of Verona Pharma plc from February 2020 until its acquisition by Merck in October 2025.
  • From 2018 until its acquisition by Swedish Orphan Biovitrum AB ("Sobi") in November 2019, Dr. Zaccardelli served as President and CEO and on the board of directors of Dova Pharmaceuticals, a U.S. company developing therapeutics for rare diseases.

Tools for this story

Each opens in a new tab, filled in for SAB Biotherapeutics, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/sab-biotherapeutics
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
What changed at the top of SAB Biotherapeutics, Inc.? (2026). MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/sab-biotherapeutics